Segments (Tables)

3 Months Ended

Mar. 31, 2026

Segment Reporting [Abstract]

Schedule of Drug Development Segment and Reconciliation to Consolidated Net (Loss) Income Segment Operations

The table below provides information about the Company's drug development segment and includes the reconciliation to consolidated net loss for the three months ended March 31, 2026 and 2025, respectively (in thousands):


		Three Months Ended March 31,
		2026				2025
Revenue		$	—			$	257
Less:
Clinical expense			2,015				1,712
Preclinical expense			247				937
Chemistry, manufacturing, and controls			555				500
IPR&D expense (Note 10)			8,000				—
Selling, general, and administrative			4,588				3,726
Interest expense			—				173
Plus:
Interest income			(535	)			(776	)
Other segment expense (income) (1)			6,429				(624	)
Segment net loss			(21,299	)			(5,391	)
Reconciliation of segment net loss
Adjustments and reconciling items			—				—
Consolidated net loss		$	(21,299	)		$	(5,391	)

(1) Other segment expense (income) includes other research and development expense, amortization of debt issuance costs and discount, other income, and the warrant liabilities fair value adjustment.